WHY BETA-BLOCKERS ARE NOT PRESCRIBED TO PATIENTS WITH HEART FAILURE AND HOW TO IMPROVE IT?

Aim. To determine indications for differential prescription of beta-blockers in patients with chronic heart failure (CHF) and to study efficacy and safety of beta-blockers therapy.

Material and Methods. Patients (n=90; 55.6% of men; aged 64.7±1.9 y.o.) with CHF class 3-4 NYHA of ischemic and non-ischemic etiology with inadequate treatment with beta-blockers were included in the study. Patients were randomized into 3 groups depending on received beta-blocker: group 1 (n=30) — bisoprolol, group 2 (n=30) — carvedilol, group 3 (n=30) — nebivolol. Study duration was 6 months. Clinical examination (physical, laboratory and instrumental tests) and assessment of the adverse events was performed at baseline and after 6 months. Multiple regression analysis was performed to determine the probability of efficiency achievement by using different parameters (target heart rate, mortality, side effects, hospitalization, 6-minute walk test, left ventricle ejection fraction (LV EF), glomerular filtration rate).

Results. Significant increase in LV EF was found: in group 1 from 32.4±6.1 to 47.2±4.1% (p=0.049); in group 2 from 31.3±8.4 to 46.5±4.2% (p=0.047); in group 3 from 30.3±6.9 to 46.8±4.0% (p=0.043). Class NYHA decreased in group 1 from 3.5±0.5 to 2.3±0.3 (p=0.044); in group 2 from 3.4±0.6 to 2.1±0.2 (p=0.045) and in group 3 from 3.6±0.4 to 2.4±0.4 (p=0.038). The hospitalization rate due to heart failure decompensation was 16.7, 16.7 and 13.3%, respectively. Mortality in groups during 6 months was 6.7, 0.0 and 3.3%, respectively. The efficacy of CHF therapy with betablockers depended on comorbidity and demographic characteristics. The highest refractoriness to CHF therapy was in patients with chronic kidney failure, atrial fibrillation and anemia (odds efficiency was 2.2, 2.9 and 3.1%, respectively). Bisoprolol was the most effective beta-blocker for the CHF patients treatment according to the majority of dependent variables in multiple regression analysis (p=22.13 vs. 20.66 for carvedilol and 18.69 for nebivolol).

Conclusion. A differentiated approach to the beta-blocker prescription depending on the initial clinical and demographic patient characteristics can improve efficacy of the CHF treatment.

1. Tereshchenko S.N., Dzhaiani N.A., Zhirov I.V., Uskach T.M. Chronic heart failure. Problems of diagnosis and treatment. M.: Anakharsis; 2006. Russian (Терещенко С.Н., Джаиани Н.А., Жиров И.В., Ускач Т.М. Хроническая сердечная недостаточность. Вопросы диагностики и лечения. М.: Анахарсис; 2006).

2. Belenkov Yu.N., Mareev V.Yu., Ageev F.T. Chronic heart failure. Selected lectures on cardiology. M.: GEOTAR; 2006. Russian (Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т. Хрони- ческая сердечная недостаточность. Избранные лекции по кардиологии. М.: ГЭОТАР; 2006).

3. National recommendations of VNOK and SSHF on the diagnostics and treatment of chronic heart failure (third review). Serdechnaya nedostatochnost 2010; 11(1):1-40. Russian (Национальные рекомендации по диагностике и лечению хронической сердечной недостаточности (третий пересмотр). Комитет экспертов ВНОК и ОССН. Сердечная недостаточность 2010; 11(1): 1-40).

4. Viskin S., Kitzis I., Lev E. et al. Treatment with beta-adrenergic blocking agents after myocardial infarction: from randomized trials to clinical practice. J Am Coll Cardiol 1995; 25(6): 1327- 1332.

5. Gottlieb S.S., McCarter R.J., Vogel R.A. Effect of beta-blockade on mortality among highrisk and low risk patients after myocardial infarction. N EnglJ Med 1998; 339(8): 489-497

6. Ageev F.T., Danielyan M.O., Mareev V.Yu. et al. Patients with chronic heart failure in Russia's outpatient practice: the contingent features, diagnosis and treatment (studies of EPOHA-O-HSN). Serdechnaya nedostatochnost 2004;5 (1):4–7. Russian (Агеев Ф.Т., Даниелян М.О., Мареев В.Ю. и др. Больные с хронической сердечной недостаточностью в российской амбулаторной практике: особенности контингента, диагностики и лечения (по материалам исследования ЭПОХА–О–ХСН).Сердечная недостаточность2004;5 (1):4–7).

7. Ageev F.T., Belenkov Yu.N., Fomin I.V. et al. Prevalence of chronic heart failure in the European part of Russia – the data of EPOHA-HSN. Serdechnaya Nedostatochnost 2006;7 (1): 112–115 (Агеев Ф.Т., Беленков Ю.Н., Фомин И.В. и др. Распространенность хронической сердечной недостаточности в Европейской части Российской Федерации — данные ЭПОХА–ХСН. Сердечная Недостаточность 2006;7 (1): 112–115).

8. Swedberg К., Komajda М., Bohm М. et al. on behalf of the SHIFT Investigators. Ivabradine and outcomes in chronic heartfailure (SHIFT): a randomised placebo-controlled study. Lancet 2010;376(9744):875-85.

9. Castagno D., Jhund P., McMurray J. et al. Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial. Eur J Heart Fail 2010; 12(6): 607–616.

10. Konishi M., Haraguchi G., Kimura S. et al. Comparative Effects of Carvedilol vs Bisoprolol for Severe Congestive Heart Failure. Circ J 2010; 74(6): 1127–1134.